Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal ...

Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid ...

Lilly's Zepbound overtook Novo's Wegovy as the leading obesity drug, according to the latest prescription data last month. But Novo CEO Lars Jørgensen attributes the softness in sales to the ...

Novo reported $11.9 billion in revenues, in line with Wall Street's estimates, and beat on adjusted earnings per share (EPS) ...

As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity ...

Wegovy sales expected to recover after FDA ban on copycats Guidance for 2025 sales, profit both cut Slower US obesity market penetration Q4 sales narrowly miss, profits beat Shares up 3.4% ...

Novo Nordisk's Q1 results show a dramatic expansion in sales beyond the US. Nevertheless, issues remain, and its outlook for ...

The weight-loss drug revolution is reshaping the health and wellness industry, forcing companies to adapt or face the same ...

COPENHAGEN/LONDON (Reuters) -Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound copycats is enforced this month ...